GLOBAL X ETF ICAV Shareholder Notice EGM- EDOC LN

Unless otherwise defined herein, all capitalised terms used in this Circular shall bear the same meaning as capitalised terms used in the latest prospectus of the ICAV dated 26 March 2025 (the "Prospectus"). A copy of the Prospectus and the supplement for the Fund (the "Supplement") is available upon request during normal business hours from the ICAV or from the local representative of the ICAV in any jurisdiction in which the ICAV is registered for public distribution.

The Directors of the ICAV accept responsibility for the information contained in this Circular. To the best of the knowledge and belief of the Directors (who have taken all reasonable care to ensure that such is the case) the information contained in this Circular is in accordance with the facts and does not omit anything likely to affect the import of such information.

RE:       Global X Telemedicine and Digital Health UCITS ETF

Notification of an extraordinary general meeting to change the investment objective of the Fund

25 April 2025

Dear Shareholder,

1.         INTRODUCTION

The ICAV is an open-ended investment vehicle with variable capital organised under the laws of Ireland and is authorised by the Central Bank pursuant to the European Communities (Undertakings for Collective Investment in Transferable Securities) Regulations 2011, as amended (the "UCITS Regulations").  The Fund is a sub-fund of the ICAV.

The purpose of this Circular is to: (i) notify you of an extraordinary general meeting ("EGM") to consider, and vote on, a proposed change of Index for the Fund, which amendment  would constitute a change to the investment objective of the Fund (the "Material Change"); and (ii) notify you that in the event the vote to implement the Material Change is successful, there would be a change to the name of the Fund to reflect the new Index, a fee reduction and tracking error update (the "Non-Material Changes"). For the avoidance of doubt, Shareholders will not be asked to vote on the Non-Material Changes. These will be implemented should the vote on the Material Change be successful.

2.       MATERIAL CHANGE

2.1        Index Change

The current investment objective of the Fund is to replicate the performance of the Solactive Telemedicine & Digital Health Index (the "Index"). It is proposed to change the Index so that the investment objective of the Fund will be to replicate the performance of the Mirae Asset HealthTech Index (the "New Index"). A full description of the New Index can be found at Appendix I.

Rationale

The change of Index is being proposed to better capture the opportunities for healthcare innovation.   In the view of the Directors and the Investment Manager, the opportunities in telemedicine adoption have plateaued post-pandemic, and the new index will allow the Fund to capture the broader digital health transformation areas that continue to accelerate.  We believe this will provide a better investment opportunity for investors in the Fund than the current index.

Subject to the Non-Material Changes detailed below, the replacement of the Index with the New Index will have no impact on the manner in which the Fund is managed. The Fund will continue to employ a full replication strategy and may make use of the increased diversification limits available under Regulation 71 of the UCITS Regulations to hold up to 35% of its Net Asset Value in one constituent of the New Index.

Investors should note that:

Shareholders shall incur no additional costs arising from the Material Change. The only costs shall be transaction costs payable in the ordinary course of portfolio rebalances.

Shareholders will also not bear any additional legal or administrative costs as a result of the proposed Material Change.

As a result of the Material Change, the Total Expense Ratio will be will reduced from 0.68% of the Net Asset Value per Share to 0.50% of the Net Asset Value per Share for distribution and accumulating share classes and from 0.68% of the Net Asset Value per Share to 0.55% of the Net Asset Value per Share for hedged share classes.

The anticipated tracking error will increase from 0.30% to 1.0% (annualised) but the risk profile of the Fund are expected to remain the same if the Material Change is implemented.

Subject to Shareholder approval being obtained, the Material Change will take effect from the date of issuance of an updated Supplement. This is expected to occur on or before the 30 May 2025, subject to Central Bank approval (the "Effective Date"). As further detailed in section 3, below, the Non-Material Changes will also take effect on the Effective Date.

Recommendation:

The Directors believe that the resolution relating to the Material Change to be proposed at the EGM is in the best interests of Shareholders of the Fund and, accordingly, the Directors recommend that Shareholders vote in favour of the resolution.

2.2        Notice of EGM to Consider and Vote on the Material Change

In order to obtain Shareholder approval for the Material Change, the Board has decided to convene an EGM which will be held at the registered office of the ICAV on 19 May 2025 at 10:00am (Irish time) and at which an ordinary resolution to approve the Material Change will be proposed. 

Please note that you are only entitled to attend and vote at the EGM (or any adjournment thereof) if you are a registered Shareholder. As the ICAV uses the International Central Securities Depositary (ICSD) model of settlement and the Common Depositary Nominee is the sole registered Shareholder of Shares in the Fund, investors in the Fund should submit their voting instructions through the relevant ICSD or the relevant participant in an ICSD (such as a local central securities depositary, broker or nominee). If any investor has invested in the Fund through a broker/dealer/other intermediary, the investor should contact this entity to provide voting instructions.

2.3        Proxy Form / Shareholders unable to attend the EGM

The form of proxy accompanying this Circular should be completed and returned in accordance with the instructions thereon, so as to be received no later than 48 hours before the time fixed for the holding of the EGM.

2.4        Re-convening the EGM

Should it be necessary to re-convene the EGM, Shareholders should note that the Board has determined that the re-convened meeting would take place on the 26^th of May 2025 at 10:00am (Irish time).

2.5        Publication of Results

The result of the EGM will be announced through the regulatory news service on the London Stock Exchange website and will be published in an appropriate manner in each of the other jurisdictions in which the Shares of the Fund are listed on a stock exchange.

3.       NON-MATERIAL CHANGES

3.1        Name Change

As a result of the Material Change, it is proposed to change the name of the Fund to Global X HealthTech UCITS ETF to reflect the name of the New Index in the name of the Fund.

3.2        TER

As a result of the Material Change, the Total Expense Ratio will be will reduced from 0.68% of the Net Asset Value per Share to 0.50% of the Net Asset Value per Share for distribution and accumulating share classes and from 0.68% of the Net Asset Value per Share to 0.55% of the Net Asset Value per Share for hedged share classes.

3.3        Tracking Error

As a result of the Material Change, the Fund's anticipated tracking error will increase from 0.30% to 1.0% (annualised).

4.       REDEMPTION OF SHARES

Shareholders who do not wish to remain in the Fund following the implementation of the Material Change and/or the Non-Material Changes (if the ordinary resolution is passed) will have the opportunity to redeem their Shares on any Dealing Day prior to the Effective Date by contacting the Administrator so that a written redemption request is received by the Administrator by the Dealing Deadline for the relevant Dealing Day.

Should you have any questions relating to these matters, you should either contact us at the above address or alternatively you should contact your investment consultant.

Yours sincerely,

________________

Director

for and on behalf of

Global X ETFs ICAV

GLOBAL X ETFS ICAV

(an umbrella fund with segregated liability between sub-funds)

(the "ICAV")

NOTICE OF EXTRAORDINARY GENERAL MEETING

Notice is hereby given that an extraordinary general meeting of the shareholders of the Global X Telemedicine and Digital Health UCITS ETF (the "Fund"), a sub-fund of the ICAV, will be held at 10 Earlsfort Terrace, Dublin 2, D02 T380, Ireland at 10:00 am (Irish time) on 19 May 2025 to consider, and if thought fit, pass the following resolution as an ordinary resolution of the shareholders of the Fund:

"That the Investment Objective of the Fund will be to replicate the performance of the Mirae Asset HealthTech Index (the "New Index"). A full description of the New Index can be found at Appendix I of the shareholder circular accompanying this notice be and are hereby amended by the adoption of New Index of the Fund."

BY ORDER OF THE BOARD

SIGNED:         _______________________________

For and on behalf of Bradwell Limited

                        Secretary to the ICAV

Registered Office:        10 Earlsfort Terrace,

Dublin 2

D02 T380

Ireland

Dated: 25 April 2025

NOTE

Every shareholder entitled to attend and vote at the above meeting is entitled to appoint a proxy to attend, speak and vote in his stead.  A body corporate may appoint an authorised representative to attend, speak and vote on its behalf.  A proxy or an authorised representative need not be a shareholder of the ICAV. Shareholders may return a signed copy of the proxy form, for the attention of Ms. Claire McKeague, either by post to the secretary of the ICAV at Bradwell Limited, 10 Earlsfort Terrace, Dublin 2, D02 T380, Ireland, or electronically to [email protected] to arrive no later than 48 hours before the time of the meeting. Completion and return of a proxy form will not preclude a shareholder from attending and voting in person at the extraordinary general meeting.

GLOBAL X ETFS ICAV

(an umbrella fund with segregated liability between sub-funds)

(the "ICAV")

FORM OF PROXY

I                                                                                                                                                          

on behalf of                                                                                                                                        

being a shareholder of the Global X Telemedicine and Digital Health UCITS ETF (the "Fund"), a sub-fund of the ICAV, hereby appoint the Chairperson of the meeting or failing him/her, Ms. Claire McKeague, Ms. Laura McClements, Ms. Tara O'Reilly, Ms. Dearbhla O'Sullivan, Ms. Stephanie Hanrahan or Ms. Hannah Grouse, of Arthur Cox LLP, 10 Earlsfort Terrace, Dublin 2, D02 T380, Ireland or failing him/her________________________ or failing him/her___________________, and each of them separately, as my proxies (each, a "Proxy"), and hereby authorise each of them to vote my/our shares in the Fund which I/we would be entitled to vote at the extraordinary general meeting of the Fund to be held at 10 Earlsfort Terrace, Dublin 2, D02 T380, Ireland at 10:00 am (Irish time) on 19 May 2025 and at any postponements or adjournments thereof, as fully as I/we would be entitled to vote if personally present.

Signed:                         _______________________________________________

Name in block capitals:                                                                                                          

Dated this                    day of                                                  2025

Please indicate with an "X" in the box below how you wish the Proxy to vote.

Otherwise, the Proxy will vote as he or she thinks fit.

NOTES:         

1.         Unless otherwise instructed, the Proxy will vote as he or she thinks fit.

2.         This instrument of Proxy, to be valid, must be sent to arrive, or be lodged, at the address printed below not later than 48 hours before the time fixed for the meeting.

3.         In the case of a corporate shareholder, this instrument may be either under its common seal or under the hand of an officer or attorney authorised on its behalf.

4.         For omnibus/nominee shareholders, who without going to underlying investors do not have the authority to vote, please indicate how you wish your Proxy/representative to vote by inserting the aggregate number of underlying investor votes "for", "against" or "abstain" in the relevant box.

5.         If you wish to appoint a Proxy other than the Chairperson of the meeting or the Arthur Cox LLP staff listed directly after the Chairperson, please cross them out and insert the name of the chosen Proxy or Proxies in the space(s) provided.

6.         If this instrument is signed and returned without any indication of how the person appointed Proxy shall vote, he will exercise his discretion as to how he votes and whether or not he abstains from voting.

7.         In the case of joint shareholders, the vote of the shareholder who tenders a vote whether in person or by Proxy, shall be accepted to the exclusion of the votes of the other joint holders and for this purpose seniority should be determined by the order in which the names stand in the register of shareholders in respect of the joint holding.

8.         Any alterations made to this form must be initialled.

9.         Shareholders may return a signed copy of the Proxy form, for the attention of Ms. Claire McKeague, either by post to the secretary of the ICAV at Bradwell Limited, 10 Earlsfort Terrace, Dublin 2, D02 T380, Ireland, or electronically to [email protected] to arrive no later than 48 hours before the time of the meeting. Completion and return of a Proxy form will not preclude a shareholder from attending and voting in person at the extraordinary general meeting.

Appendix I

Description of the New Index

Mirae Asset HealthTech Index

_______

2024.12.16